What specific areas of research meet the criteria for ASPIRE Rheumatology and Inflammatory Bowel Disease funding?

What specific areas of research meet the criteria for ASPIRE Rheumatology and Inflammatory Bowel Disease funding?
Research proposals are should aim to further the understanding of selected rheumatologic disorders and diseases or inflammatory bowel disease. Specifically, proposals are sought that have the potential to enhance care for patients with selected rheumatology conditions or those with inflammatory bowel disease. Research areas of interest are as follows:

General

  • Approaches to improving communication among patients and healthcare providers (e.g., enduring materials, technological advancements, or web-based teaching programs)
  • Health economic and outcomes research related to selected autoimmune diseases
  • Basic research in the etiology of selected autoimmune and inflammatory diseases in rheumatology or gastroenterology.

Rheumatologic Disorders and Diseases

Conditions of interest include, but are not limited to: RA, PsA, SLE, and ILD.

  • Use of biomarkers, ultrasound and magnetic resonance imaging (MRI) in assessment and management of RA
  • Comorbid conditions, such as diabetes, cardiovascular, pulmonary, or ophthalmologic, and increased risks with concomitant therapies used to treat these comorbidities (including, but not limited to, epidemiology, overlapping pathogenesis, assessment, and management of these conditions)
  • Approaches to improving adherence to therapy
  • Approaches to improving management such as: treating to a specific goal or target by monitoring response and adjusting therapy; evidence-based treatment algorithms; factors predictive of response to therapy
  • Signaling pathways implicated in pathogenesis
  • Kinase inhibitors and other small molecules that are not being studied currently by a company competing with Pfizer Inc.

Inflammatory bowel disease

  • Exploration of the role of JAK/STAT pathways in pathogenesis of inflammatory bowel disease
  • Use of biomarkers (of any type) to predict response to treatment, disease course, or to differentiate between Crohn's disease and ulcerative colitis
  • Approaches to improving disease management (e.g. evaluation of sequencing of therapy, treating to a specific goal or target)
  • Evaluation of the increased risk of cardiovascular disease in patients with IBD (top)

FAQ Category:

FAQ Tag: 
criteria